Skip to main content
Article thumbnail
Location of Repository

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

By Stephen B Hanauer, William J Sandborn, Christian Dallaire, André Archambault, Bruce Yacyshyn, Chyon Yeh and Nancy Smith-Hall
Topics: Original Article
Publisher: Pulsus Group Inc
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.